Rational therapy for diabetes: Early recognition of adverse effects and avoidance of disruptive false alarms

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 4, 2012, Pages 321-324

  Raz, Itamar ^a   Eldor, Roy ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

"Mini sentinel" program; "Sentinel" program; Adverse Events Reporting System (AERS); Diabetes; Diabetes treatment; Exenatide pioglitazon saxagliptin; False alarms; Insulin glargine; Liraglutide pancreatitis; Lovastatin; Rosiglitazone; Sitagliptin; Therapy

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; INSULIN GLARGINE; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN;

AUTHOR; DATA BASE; DIABETES MELLITUS; DRUG INFORMATION; EARLY DIAGNOSIS; HUMAN; MEDICAL LITERATURE; NOTE; PANDEMIC; PRIORITY JOURNAL; PUBLICATION; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84860891303     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2265     Document Type: Note

References (32)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
2. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008.
3. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38.
4. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
5. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120: 2529-2540.
6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
7. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
8. Bilous RW. Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis? Diabet Med 2007; 24: 931-933.
9. Bloomgarden ZT. The Avandia debate. Diabetes Care 2007; 30: 2401-2408.
10. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147: 578-581.
11. Mulrow CD, Cornell J, Localio AR. Rosiglitazone: a thunderstorm from scarce and fragile data. Ann Intern Med 2007; 147: 585-587.
12. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009; 339: b2942.
13. Loebstein R, Dushinat M, Vesterman-Landes J, et al. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol 2011; 51: 173-180.
14. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-2643.
15. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 342. DOI: 10.1136/bmj.d1309.
16. FDA significantly restricts access to the diabetes drug Avandia, 2010.
17. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-1744.
18. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754.
19. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5year randomised, open-label study. Diabetologia 2009; 52: 1971-1973.
20. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755-1765.
21. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52: 2499-2506.
22. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141(1): 150-156.
23. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009; 58: 2148-2161.
24. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009; 58: 1604-1615.
25. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2011; 53: 153-159.
26. Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2011; 299: E1076-E1086.
27. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
28. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13: 559-566.
29. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System - a national resource for evidence development. N Engl J Med 2011; 364: 498-499.
30. Selby J, Fireman B, Butler M. Report to FDA on a protocol for active surveillance of acute myocardial infarction in association with the use of a pharmaceutical agent, 2010.
31. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
32. Yang X, Chan JC. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care 2011; 34: e136.